EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FXR agonists in NASH treatment

Luciano Adorini, Michael Trauner

Journal of Hepatology · 2023-11 · 79 (5) · 1317-1331

DOI: 10.1016/j.jhep.2023.07.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Hepatology, 2023-11. Verfasst von Luciano Adorini und 1 weiteren Autor:innen. Beteiligte Einrichtung: Intercept Pharmaceuticals Inc., 305 Madison Ave., Morristown, NJ 07960, USA. Electronic address: ladorini@interceptpharma.com. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 193-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed in the liver and intestine, regulates the expression of genes involved in cholesterol and bile acid homeostasis, hepatic gluconeogenesis, lipogenesis, inflammation and fibrosis, in addition to controlling intestinal barrier integrity, preventing bacterial translocation and maintaining gut microbiota eubiosis. Non-alcoholic steatohepatitis (NASH), an advanced stage of non-alcoholic fatty liver disease, is characterized by hepatic steatosis, hepatocyte damage (ballooning) and inflammation, leading to fibrosis, cirrhosis and hepatocellular carcinoma. NASH represents a major unmet medical need, but no pharmacological treatments have yet been approved. The pleiotropic mechanisms involved in NASH development offer a range of therapeutic opportunities and among them FXR activation has emerged as an established pharmacological target. Various FXR agonists with different physicochemical properties, which can be broadly classified as BA derivatives, non-BA-derived steroidal FXR agonists, non-steroidal FXR agonists, and partial FXR agonists, are in advanced clinical development. In this review we will summarize key preclinical and clinical features of the most advanced FXR agonists and critically evaluate their potential in NASH treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseReceptors, Cytoplasmic and NuclearHumansAnimalsBile Acids and SaltsLiver

Stichwörter der Autor:innen

Farnesoid X receptor agonistscombination therapyliver fibrosisnon-alcoholic steatohepatitisrandomized controlled trials

Substanzen

Receptors, Cytoplasmic and NuclearBile Acids and Salts

Autor:innen und Institutionen

  • Intercept Pharmaceuticals Inc., 305 Madison Ave., Morristown, NJ 07960, USA. Electronic address: ladorini@interceptpharma.com.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Electronic address: michael.trauner@meduniwien.ac.at.

Zitieren

APA

Adorini, L., & Trauner, M. (2023). FXR agonists in NASH treatment. Journal of Hepatology, 79(5), 1317-1331. https://doi.org/10.1016/j.jhep.2023.07.034

Vancouver

Adorini L, Trauner M. FXR agonists in NASH treatment. Journal of Hepatology. 2023;79(5):1317-1331. doi:10.1016/j.jhep.2023.07.034

BibTeX
@article{Adorini2023,
  author = {Adorini, Luciano and Trauner, Michael},
  title = {FXR agonists in NASH treatment},
  journal = {Journal of Hepatology},
  year = {2023},
  volume = {79},
  number = {5},
  pages = {1317--1331},
  doi = {10.1016/j.jhep.2023.07.034}
}
Kostenlos starten →